TScan Therapeutics TCRX Stock
TScan Therapeutics Price Chart
TScan Therapeutics TCRX Financial and Trading Overview
| TScan Therapeutics stock price | 1.6 USD |
| Previous Close | 2.67 USD |
| Open | 2.6 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 1100 |
| Day's Range | 2.57 - 2.74 USD |
| 52 Week Range | 1.45 - 6.03 USD |
| Volume | 120.7K USD |
| Avg. Volume | 1.47M USD |
| Market Cap | 129.24M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.5 USD |
TCRX Valuation Measures
| Enterprise Value | 54.39M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.7705383 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.462934 |
| Price/Book (mrq) | 0.8447205 |
| Enterprise Value/Revenue | 3.141 |
| Enterprise Value/EBITDA | -0.802 |
Trading Information
TScan Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | -11.97% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 6.03 USD |
| 52 Week Low | 1.45 USD |
| 50-Day Moving Average | 2.7 USD |
| 200-Day Moving Average | 2.56 USD |
TCRX Share Statistics
| Avg. Volume (3 month) | 1.47M USD |
| Avg. Daily Volume (10-Days) | 394.2K USD |
| Shares Outstanding | 42.77M |
| Float | 12.86M |
| Short Ratio | 0.13 |
| % Held by Insiders | 6.90% |
| % Held by Institutions | 64.27% |
| Shares Short | 499.88K |
| Short % of Float | 1.34% |
| Short % of Shares Outstanding | 1.05% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -422.79% |
| Gross Margin | -286.37% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -26.77% |
| Return on Equity (ttm) | -64.92% |
Income Statement
| Revenue (ttm) | 17.32M USD |
| Revenue Per Share (ttm) | 0.72 USD |
| Quarterly Revenue Growth (yoy) | 125.20% |
| Gross Profit (ttm) | -46284000 USD |
| EBITDA | -67775000 USD |
| Net Income Avi to Common (ttm) | -72628000 USD |
| Diluted EPS (ttm) | -2.92 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 95.61M USD |
| Total Cash Per Share (mrq) | 3.95 USD |
| Total Debt (mrq) | 85.31M USD |
| Total Debt/Equity (mrq) | 109.35 USD |
| Current Ratio (mrq) | 7.184 |
| Book Value Per Share (mrq) | 3.22 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -69966000 USD |
| Levered Free Cash Flow (ttm) | -48413500 USD |
Profile of TScan Therapeutics
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 830 Winter Street |
| ZIP | 02451 |
| Phone | 857 399 9500 |
| Website | https://www.tscan.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 136 |
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors. The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors. In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Q&A For TScan Therapeutics Stock
What is a current TCRX stock price?
TScan Therapeutics TCRX stock price today per share is 1.6 USD.
How to purchase TScan Therapeutics stock?
You can buy TCRX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for TScan Therapeutics?
The stock symbol or ticker of TScan Therapeutics is TCRX.
Which industry does the TScan Therapeutics company belong to?
The TScan Therapeutics industry is Biotechnology.
How many shares does TScan Therapeutics have in circulation?
The max supply of TScan Therapeutics shares is 60.83M.
What is TScan Therapeutics Price to Earnings Ratio (PE Ratio)?
TScan Therapeutics PE Ratio is now.
What was TScan Therapeutics earnings per share over the trailing 12 months (TTM)?
TScan Therapeutics EPS is -1.14 USD over the trailing 12 months.
Which sector does the TScan Therapeutics company belong to?
The TScan Therapeutics sector is Healthcare.
TScan Therapeutics TCRX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
| NYSE COMPOSITE (DJ) NYA | 18899.8 USD — |
+0.02
|
— — | 18743.76 USD — | 18909.46 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1839.71 USD — |
-3.16
|
— — | 1825.54 USD — | 1881.06 USD — | — - | — — |
- {{ link.label }} {{link}}